-
Power target Polθ: the potential to burst into the game
Time of Update: 2021-10-23
DNA polymerase theta (Polθ or POLQ) is a synthetic lethal target with homologous recombination (HR) defects, and plays an important role in the DNA damage response (DDR) pathway of double-strand breaks (DSB) .
-
Murderous!
Time of Update: 2021-10-23
After the companies are shortlisted, according to the proposed selection rules, the price reductions of all A competition units of the 17 product groups are ranked from high to low, and the top 70% of the companies (rounded to the nearest integer, the same below) are directly eligible for the proposed selection.
-
The Biden administration initiated the drug price negotiation bill. The CEOs all voiced that the US prescription drug prices will be reduced?
Time of Update: 2021-10-23
The bill triggered strong opposition from the pharmaceutical industry, including CEOs of companies such as AbbVie, BMS, Eli Lilly, and GSK, all expressed concern or even opposition to this increase in control of drug pricing .
-
Nanjing Chia Tai Tianqing is showing off! Enter Novartis to grab the first copy of $2 billion large variety
Time of Update: 2021-10-23
On September 18, Nanjing Chia Tai Tianqing submitted an application for the imitation of 4 types of sacubitril and valsartan sodium tablets .
Figure 2: Sales of Novartis' sacubatril and valsartan sodium tablets in the retail market (unit: ten thousand yuan)Source: China City Entity Pharmacy Database of MeinenetAccording to data from Meinnet.
-
Hengrui JAK1 inhibitor phase II clinical trial for alopecia areata reached the primary endpoint
Time of Update: 2021-10-23
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn August 24, Hengrui announced that the Phase II clinical study RSJ10521 (CRYSTAL2) of the SHR0302 tablet for the treatment of alopecia areata developed by its subsidiary Ruishi Biotechnology has reached the primary study endpoint .
-
The follow-up to the national adoption of the abandonment standard: the replacement company has been determined!
Time of Update: 2021-10-23
The announcement showed that because North China Pharmaceutical failed to supply drugs in accordance with the agreed procurement volume, the joint procurement member units collectively After deliberation, it was decided to include it on the "list of violations" and cancel the company's qualification to participate in the centralized drug procurement activities organized by the state from August 11, 2021 to May 10, 2022 .
-
Qilu "Rigofinil" reported to be listed on the market, no generic drugs have been approved in China
Time of Update: 2021-10-23
On March 24, 2013, the original CFDA approved its listing for the treatment of metastatic colorectal cancer that has previously received fluorouracil, oxaliplatin and irinotecan-based chemotherapy and anti-EGFR treatment (RAS wild-type) ( mCRC) patients, and locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) patients who have previously been treated with imatinib mesylate and sunitinib malate .
-
CStone Pharmaceuticals will announce the registration clinical trial data of sugarizumab in the treatment of stage III non-small cell lung cancer in the form of an oral report at the 2021 European Society of Medical Oncology (ESMO) annual meeting
Time of Update: 2021-10-23
Suzhou, September 17, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, today Announced that at the 2021 European Society of Medical Oncology (ESMO) annual meeting, the registered clinical study GEMSTONE-301 for the treatment of stage III non-small cell lung cancer (NSCLC) with sugarizumab was selected as a late-breaking abstract at the ESMO annual meeting.
-
From next year!
Time of Update: 2021-10-23
On January 1, 2022, Zhejiang formally implemented the "Specified Evaluation Rules for Medical Insurance Designated Retail Pharmacies", making it more difficult to approve medical insurance designated pharmacies .
-
330 million dollars!
Time of Update: 2021-10-23
Article source: Medical Rubik's Cube InfoEli Lilly announced today that the US government has purchased additional neutralizing antibody therapy authorized by it for emergency use to treat COVID-19 .
In February 2021, the US government purchased at least 100,000 doses of diabody therapy drugs worth US$210 million from Eli Lilly .
-
PD-(L)1 Dual Anti-Partner Heat Competition: TGFβ Throne Steady and 4-1BB Strongly Rise
Time of Update: 2021-10-23
Before 2021, including Merck, only these four domestic products have entered the clinical stage, but in 2021 ushered in the peak of the declaration of PD-(L)1/TGFβ dual-target drugs.
-
Innovent's 2 bispecific antibodies were approved for clinical use
Time of Update: 2021-10-23
Retrieved Sep 14, 2021, from https:// Phase 1 clinical study of anti-CD47/PD-L1 bispecific antibody completed the first patient administration in China.
-
Kunyao Group valsartan and amlodipine tablets (Ⅰ) obtained the drug registration certificate
Time of Update: 2021-10-23
The company's valsartan and amlodipine tablets (I) were approved by the State Food and Drug Administration according to category 4 chemical drugs, and they were deemed to have passed the consistency evaluation .
-
The urgency of China's innovative drugs
Time of Update: 2021-10-23
Among them, for the biomedical industry, the top-level design is striving to build China's biomedical innovation ecology in terms of drug review, medical insurance, pricing, or in terms of promoting capital assistance and talent gathering.
-
10 years of CSCO: the golden years of new cancer drugs in China
Time of Update: 2021-10-23
At that time, multi-targeted TKI was still "sweet and sweet"-the world's first small-molecule anti-angiogenesis targeted drug approved for the treatment of advanced gastric cancer emerged, but today it seems that apatinib has expanded after its launch in 2014 The pace of the indication was not smooth, and it was not until January this year that the second indication (second-line advanced liver cancer) was finally approved .
-
MedAlliance announces completion of Japanese research recruitment
Time of Update: 2021-10-23
Geneva, September 24, 2021/PRNewswire/ - MedAlliance and its Japanese partner MDK Medical have completed the clinical trial of its new sirolimus drug-eluting balloon (DEB) SELUTION SLR™ for the treatment of peripheral arterial disease (PAD) Research recruitment .
-
Puli Pharmaceutical's desloratadine dry suspension passed the EU technical review
Time of Update: 2021-10-23
On August 23, Hainan Puli Pharmaceuticals issued an announcement stating that the company recently received an End of Procedure from the European Commission for the Evaluation of Drugs (CBG), which means that the company’s desloratadine dry suspension The drug has successfully passed the review by the Dutch Drug Evaluation Board (CBG) and the German Federal Agency for Drugs and Medical Devices (BfArM), and will soon be approved for marketing in the Netherlands and Germany .
-
Pfizer/BioNTech submits to the FDA the marketing application for the third dose of mRNA COVID-19 vaccine
Time of Update: 2021-10-23
In subjects who had no evidence of SARS-CoV-2 infection within 1 month of the third dose of vaccine, COMIRNATY induced the production of powerful neutralizing antibodies against the wild-type strain .
The neutralizing antibody titer of the SARS-CoV-2 wild-type strain produced one month after the third dose was 3.
-
Hengrui lays out large indications, and Junshi is eye-catching in the sea... Where is the domestically-made PD-1 R&D internal rollout?
Time of Update: 2021-10-23
Recently, news of PD-1 frequently came out. Junshi Biotech’s teriprizumab has completed the rolling submission of the marketing application to the FDA. Drug K has been approved for the eighth indica
-
HGF monoclonal antibody is accredited by FDA Fast Track
Time of Update: 2021-10-23
In June 2021, the company announced the use of ficlatuzumab as a single agent or combined with EGFR monoclonal antibody cetuximab for relapsed or refractory metastatic head and neck squamous cells that had previously received immunotherapy, chemotherapy, and cetuximab.
